NUCLEIC ACIDS RES 润色咨询

NUCLEIC ACIDS RESEARCH

出版年份:暂无数据 年文章数:18992 投稿命中率: 开通期刊会员,数据随心看

出版周期:Semimonthly 自引率:7.1% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=859466, encodeId=c76e859466fb, content=审稿速度:1.0<br>经验分享:nar竟然是二区????????和去年pnas、nature communications“划”到二区一样夸张。好一点的学校都已经有自己的评价体系,而不是跟风中科院分区(中科院分区,中科院很多所自己都不用),情况会逐渐转好。顺便讲个真实的笑话:一个发了一作pnas的朋友去某医学院面试,人事处的老师说,你不就是发了一篇二区文章么! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9195413982, createdName=ms3860263520721591, createdTime=Wed Apr 15 16:58:51 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970593, encodeId=7c849e0593a4, content=in editorial review状态需要多久呢,我的10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52f25512562, createdName=ms2000000504554122, createdTime=Thu Jun 03 15:09:25 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567125, encodeId=644f56e1252d, content=大神,请问需要多久?<span class="quote">tomsyu 2019-01-04 发表::<br>in editorial review这个状态需要多久啊?</span><span class="quote">tomsyu 2019-01-04 00:00:00 发表:<br>in editorial review这个状态需要多久啊?</span>, beContent=tomsyu 2019-01-04 发表:: in editorial review这个状态需要多久啊?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=333, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKt8ibGpwDuX7CGf4Nf1iaeHbqWV9NQUmj1teVPeX2aMx1ic2dghlvnV2TFXibFY7SyCCAl8iaPyicrNOQA/0, createdBy=54821701295, createdName=毛毛们, createdTime=Fri Feb 22 00:00:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242045, encodeId=8b42124204531, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:微生物检测;感染学;分子诊断<br>经验分享:昨天上午刚投稿,目前在in editorial review阶段,这是去年硕士毕业以后在公司发表的第一篇文章,也是在新领域发表的第一篇文章 祝我好运~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=85a68298213, createdName=ms5000001540302513, createdTime=Tue Aug 30 14:05:37 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231564, encodeId=cd051231564fa, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:转录因子<br>经验分享:前面发过一个心得。NAR的意见比较细,reject分两种,一种是完全reject,就算你补充更多的数据也不能再投。第二种reject是可以重投,但是需要大概,文章需要重新写,数据结构需要调整,数据也需要补充。第三种reject是你们说的大修,就是光按照reviewer的要求进行大修即可。是哪一种reject,editor会明确说明。一般来说,第一种的话是觉得你的创新性不够,或者感觉核心数据有严重的问题。我们是第二种。编辑允许重新投。其中一个reviewer的意见有点苛刻。所有的western的图都嫌质量不好,另外就是感觉结论不够generalized,当然还有若干具体的修改或补充实验。其实generalized的问题比较有意思,做心脏的得道的结论非要让在肿瘤上试一下,是不是有点意思。不管怎么样吧,继续努力,希望运气能好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Sat Jul 09 23:52:47 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141273, encodeId=1e3421412e3a5, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:05-Sep-2022 一轮送审<br>27-Sep-2022 大修意见回来<br>27-Feb-2023 二轮送审<br>13-Apr-2023 小修意见回来<br>04-May-2023 三轮送审<br>25-May-2023 三轮意见回来<br>25-May-2023 修改部分书面问题<br>27-May-2023 接收<br><br>总体来说,不太好投,要求比较高,补了很多实验,但大修回去后意见都很positive后,后面二轮三轮就很简单了,关键在于第一轮返修的情况。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b198299181, createdName=ms1000000281250573, createdTime=Wed Jun 07 15:29:37 CST 2023, time=2023-06-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1234512, encodeId=c59e123451205, content=第一轮评审三个审稿人,一个给了reject,一个感觉是major,还有一个minor,然后编辑给了大修<br>二审修回去一个多月了还在in peer-review,比一审还久。。感觉是不是要凉凉了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220202/98915b4d23b740819d2517eec69faee5/00e2af2d9bb645159c1b5fcddd2cb2c6.jpg, createdBy=99845449374, createdName=ms4000000106695679, createdTime=Sun Jul 24 23:31:11 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207893, encodeId=f8fd120e89306, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:癌症<br>经验分享:请问大伙,做癌症和非编码RNA投这个期刊成功率如何,最近投molecular cell悲剧,编辑要转投cell reports,但老板不让,要我再试试NC和NAR。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=科研1995师太, createdTime=Fri Apr 01 17:03:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109930, encodeId=4d9621099301b, content=二区了,还能投吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78855431602, createdName=NJMU-CNS, createdTime=Thu Jan 12 10:08:51 CST 2023, time=2023-01-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=947942, encodeId=08ae94e942eb, content=垃圾杂志,这两年火了非编码RNA否则杂志IF撑不住, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8452423117, createdName=qinss77, createdTime=Sat Mar 13 21:58:24 CST 2021, time=2021-03-13, status=1, ipAttribution=)]
    2020-04-15 ms3860263520721591

    审稿速度:1.0
    经验分享:nar竟然是二区????????和去年pnas、nature communications“划”到二区一样夸张。好一点的学校都已经有自己的评价体系,而不是跟风中科院分区(中科院分区,中科院很多所自己都不用),情况会逐渐转好。顺便讲个真实的笑话:一个发了一作pnas的朋友去某医学院面试,人事处的老师说,你不就是发了一篇二区文章么!

    5

    展开5条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=859466, encodeId=c76e859466fb, content=审稿速度:1.0<br>经验分享:nar竟然是二区????????和去年pnas、nature communications“划”到二区一样夸张。好一点的学校都已经有自己的评价体系,而不是跟风中科院分区(中科院分区,中科院很多所自己都不用),情况会逐渐转好。顺便讲个真实的笑话:一个发了一作pnas的朋友去某医学院面试,人事处的老师说,你不就是发了一篇二区文章么! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9195413982, createdName=ms3860263520721591, createdTime=Wed Apr 15 16:58:51 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970593, encodeId=7c849e0593a4, content=in editorial review状态需要多久呢,我的10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52f25512562, createdName=ms2000000504554122, createdTime=Thu Jun 03 15:09:25 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567125, encodeId=644f56e1252d, content=大神,请问需要多久?<span class="quote">tomsyu 2019-01-04 发表::<br>in editorial review这个状态需要多久啊?</span><span class="quote">tomsyu 2019-01-04 00:00:00 发表:<br>in editorial review这个状态需要多久啊?</span>, beContent=tomsyu 2019-01-04 发表:: in editorial review这个状态需要多久啊?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=333, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKt8ibGpwDuX7CGf4Nf1iaeHbqWV9NQUmj1teVPeX2aMx1ic2dghlvnV2TFXibFY7SyCCAl8iaPyicrNOQA/0, createdBy=54821701295, createdName=毛毛们, createdTime=Fri Feb 22 00:00:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242045, encodeId=8b42124204531, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:微生物检测;感染学;分子诊断<br>经验分享:昨天上午刚投稿,目前在in editorial review阶段,这是去年硕士毕业以后在公司发表的第一篇文章,也是在新领域发表的第一篇文章 祝我好运~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=85a68298213, createdName=ms5000001540302513, createdTime=Tue Aug 30 14:05:37 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231564, encodeId=cd051231564fa, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:转录因子<br>经验分享:前面发过一个心得。NAR的意见比较细,reject分两种,一种是完全reject,就算你补充更多的数据也不能再投。第二种reject是可以重投,但是需要大概,文章需要重新写,数据结构需要调整,数据也需要补充。第三种reject是你们说的大修,就是光按照reviewer的要求进行大修即可。是哪一种reject,editor会明确说明。一般来说,第一种的话是觉得你的创新性不够,或者感觉核心数据有严重的问题。我们是第二种。编辑允许重新投。其中一个reviewer的意见有点苛刻。所有的western的图都嫌质量不好,另外就是感觉结论不够generalized,当然还有若干具体的修改或补充实验。其实generalized的问题比较有意思,做心脏的得道的结论非要让在肿瘤上试一下,是不是有点意思。不管怎么样吧,继续努力,希望运气能好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Sat Jul 09 23:52:47 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141273, encodeId=1e3421412e3a5, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:05-Sep-2022 一轮送审<br>27-Sep-2022 大修意见回来<br>27-Feb-2023 二轮送审<br>13-Apr-2023 小修意见回来<br>04-May-2023 三轮送审<br>25-May-2023 三轮意见回来<br>25-May-2023 修改部分书面问题<br>27-May-2023 接收<br><br>总体来说,不太好投,要求比较高,补了很多实验,但大修回去后意见都很positive后,后面二轮三轮就很简单了,关键在于第一轮返修的情况。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b198299181, createdName=ms1000000281250573, createdTime=Wed Jun 07 15:29:37 CST 2023, time=2023-06-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1234512, encodeId=c59e123451205, content=第一轮评审三个审稿人,一个给了reject,一个感觉是major,还有一个minor,然后编辑给了大修<br>二审修回去一个多月了还在in peer-review,比一审还久。。感觉是不是要凉凉了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220202/98915b4d23b740819d2517eec69faee5/00e2af2d9bb645159c1b5fcddd2cb2c6.jpg, createdBy=99845449374, createdName=ms4000000106695679, createdTime=Sun Jul 24 23:31:11 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207893, encodeId=f8fd120e89306, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:癌症<br>经验分享:请问大伙,做癌症和非编码RNA投这个期刊成功率如何,最近投molecular cell悲剧,编辑要转投cell reports,但老板不让,要我再试试NC和NAR。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=科研1995师太, createdTime=Fri Apr 01 17:03:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109930, encodeId=4d9621099301b, content=二区了,还能投吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78855431602, createdName=NJMU-CNS, createdTime=Thu Jan 12 10:08:51 CST 2023, time=2023-01-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=947942, encodeId=08ae94e942eb, content=垃圾杂志,这两年火了非编码RNA否则杂志IF撑不住, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8452423117, createdName=qinss77, createdTime=Sat Mar 13 21:58:24 CST 2021, time=2021-03-13, status=1, ipAttribution=)]
    2021-06-03 ms2000000504554122

    in editorial review状态需要多久呢,我的10天了

    10

    展开10条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=859466, encodeId=c76e859466fb, content=审稿速度:1.0<br>经验分享:nar竟然是二区????????和去年pnas、nature communications“划”到二区一样夸张。好一点的学校都已经有自己的评价体系,而不是跟风中科院分区(中科院分区,中科院很多所自己都不用),情况会逐渐转好。顺便讲个真实的笑话:一个发了一作pnas的朋友去某医学院面试,人事处的老师说,你不就是发了一篇二区文章么! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9195413982, createdName=ms3860263520721591, createdTime=Wed Apr 15 16:58:51 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970593, encodeId=7c849e0593a4, content=in editorial review状态需要多久呢,我的10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52f25512562, createdName=ms2000000504554122, createdTime=Thu Jun 03 15:09:25 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567125, encodeId=644f56e1252d, content=大神,请问需要多久?<span class="quote">tomsyu 2019-01-04 发表::<br>in editorial review这个状态需要多久啊?</span><span class="quote">tomsyu 2019-01-04 00:00:00 发表:<br>in editorial review这个状态需要多久啊?</span>, beContent=tomsyu 2019-01-04 发表:: in editorial review这个状态需要多久啊?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=333, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKt8ibGpwDuX7CGf4Nf1iaeHbqWV9NQUmj1teVPeX2aMx1ic2dghlvnV2TFXibFY7SyCCAl8iaPyicrNOQA/0, createdBy=54821701295, createdName=毛毛们, createdTime=Fri Feb 22 00:00:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242045, encodeId=8b42124204531, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:微生物检测;感染学;分子诊断<br>经验分享:昨天上午刚投稿,目前在in editorial review阶段,这是去年硕士毕业以后在公司发表的第一篇文章,也是在新领域发表的第一篇文章 祝我好运~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=85a68298213, createdName=ms5000001540302513, createdTime=Tue Aug 30 14:05:37 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231564, encodeId=cd051231564fa, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:转录因子<br>经验分享:前面发过一个心得。NAR的意见比较细,reject分两种,一种是完全reject,就算你补充更多的数据也不能再投。第二种reject是可以重投,但是需要大概,文章需要重新写,数据结构需要调整,数据也需要补充。第三种reject是你们说的大修,就是光按照reviewer的要求进行大修即可。是哪一种reject,editor会明确说明。一般来说,第一种的话是觉得你的创新性不够,或者感觉核心数据有严重的问题。我们是第二种。编辑允许重新投。其中一个reviewer的意见有点苛刻。所有的western的图都嫌质量不好,另外就是感觉结论不够generalized,当然还有若干具体的修改或补充实验。其实generalized的问题比较有意思,做心脏的得道的结论非要让在肿瘤上试一下,是不是有点意思。不管怎么样吧,继续努力,希望运气能好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Sat Jul 09 23:52:47 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141273, encodeId=1e3421412e3a5, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:05-Sep-2022 一轮送审<br>27-Sep-2022 大修意见回来<br>27-Feb-2023 二轮送审<br>13-Apr-2023 小修意见回来<br>04-May-2023 三轮送审<br>25-May-2023 三轮意见回来<br>25-May-2023 修改部分书面问题<br>27-May-2023 接收<br><br>总体来说,不太好投,要求比较高,补了很多实验,但大修回去后意见都很positive后,后面二轮三轮就很简单了,关键在于第一轮返修的情况。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b198299181, createdName=ms1000000281250573, createdTime=Wed Jun 07 15:29:37 CST 2023, time=2023-06-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1234512, encodeId=c59e123451205, content=第一轮评审三个审稿人,一个给了reject,一个感觉是major,还有一个minor,然后编辑给了大修<br>二审修回去一个多月了还在in peer-review,比一审还久。。感觉是不是要凉凉了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220202/98915b4d23b740819d2517eec69faee5/00e2af2d9bb645159c1b5fcddd2cb2c6.jpg, createdBy=99845449374, createdName=ms4000000106695679, createdTime=Sun Jul 24 23:31:11 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207893, encodeId=f8fd120e89306, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:癌症<br>经验分享:请问大伙,做癌症和非编码RNA投这个期刊成功率如何,最近投molecular cell悲剧,编辑要转投cell reports,但老板不让,要我再试试NC和NAR。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=科研1995师太, createdTime=Fri Apr 01 17:03:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109930, encodeId=4d9621099301b, content=二区了,还能投吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78855431602, createdName=NJMU-CNS, createdTime=Thu Jan 12 10:08:51 CST 2023, time=2023-01-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=947942, encodeId=08ae94e942eb, content=垃圾杂志,这两年火了非编码RNA否则杂志IF撑不住, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8452423117, createdName=qinss77, createdTime=Sat Mar 13 21:58:24 CST 2021, time=2021-03-13, status=1, ipAttribution=)]
    2019-02-22 毛毛们

    大神,请问需要多久?tomsyu 2019-01-04 发表::
    in editorial review这个状态需要多久啊?
    tomsyu 2019-01-04 00:00:00 发表:
    in editorial review这个状态需要多久啊?

    tomsyu 2019-01-04 发表:: in editorial review这个状态需要多久啊?

    3

    展开3条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=859466, encodeId=c76e859466fb, content=审稿速度:1.0<br>经验分享:nar竟然是二区????????和去年pnas、nature communications“划”到二区一样夸张。好一点的学校都已经有自己的评价体系,而不是跟风中科院分区(中科院分区,中科院很多所自己都不用),情况会逐渐转好。顺便讲个真实的笑话:一个发了一作pnas的朋友去某医学院面试,人事处的老师说,你不就是发了一篇二区文章么! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9195413982, createdName=ms3860263520721591, createdTime=Wed Apr 15 16:58:51 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970593, encodeId=7c849e0593a4, content=in editorial review状态需要多久呢,我的10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52f25512562, createdName=ms2000000504554122, createdTime=Thu Jun 03 15:09:25 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567125, encodeId=644f56e1252d, content=大神,请问需要多久?<span class="quote">tomsyu 2019-01-04 发表::<br>in editorial review这个状态需要多久啊?</span><span class="quote">tomsyu 2019-01-04 00:00:00 发表:<br>in editorial review这个状态需要多久啊?</span>, beContent=tomsyu 2019-01-04 发表:: in editorial review这个状态需要多久啊?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=333, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKt8ibGpwDuX7CGf4Nf1iaeHbqWV9NQUmj1teVPeX2aMx1ic2dghlvnV2TFXibFY7SyCCAl8iaPyicrNOQA/0, createdBy=54821701295, createdName=毛毛们, createdTime=Fri Feb 22 00:00:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242045, encodeId=8b42124204531, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:微生物检测;感染学;分子诊断<br>经验分享:昨天上午刚投稿,目前在in editorial review阶段,这是去年硕士毕业以后在公司发表的第一篇文章,也是在新领域发表的第一篇文章 祝我好运~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=85a68298213, createdName=ms5000001540302513, createdTime=Tue Aug 30 14:05:37 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231564, encodeId=cd051231564fa, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:转录因子<br>经验分享:前面发过一个心得。NAR的意见比较细,reject分两种,一种是完全reject,就算你补充更多的数据也不能再投。第二种reject是可以重投,但是需要大概,文章需要重新写,数据结构需要调整,数据也需要补充。第三种reject是你们说的大修,就是光按照reviewer的要求进行大修即可。是哪一种reject,editor会明确说明。一般来说,第一种的话是觉得你的创新性不够,或者感觉核心数据有严重的问题。我们是第二种。编辑允许重新投。其中一个reviewer的意见有点苛刻。所有的western的图都嫌质量不好,另外就是感觉结论不够generalized,当然还有若干具体的修改或补充实验。其实generalized的问题比较有意思,做心脏的得道的结论非要让在肿瘤上试一下,是不是有点意思。不管怎么样吧,继续努力,希望运气能好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Sat Jul 09 23:52:47 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141273, encodeId=1e3421412e3a5, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:05-Sep-2022 一轮送审<br>27-Sep-2022 大修意见回来<br>27-Feb-2023 二轮送审<br>13-Apr-2023 小修意见回来<br>04-May-2023 三轮送审<br>25-May-2023 三轮意见回来<br>25-May-2023 修改部分书面问题<br>27-May-2023 接收<br><br>总体来说,不太好投,要求比较高,补了很多实验,但大修回去后意见都很positive后,后面二轮三轮就很简单了,关键在于第一轮返修的情况。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b198299181, createdName=ms1000000281250573, createdTime=Wed Jun 07 15:29:37 CST 2023, time=2023-06-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1234512, encodeId=c59e123451205, content=第一轮评审三个审稿人,一个给了reject,一个感觉是major,还有一个minor,然后编辑给了大修<br>二审修回去一个多月了还在in peer-review,比一审还久。。感觉是不是要凉凉了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220202/98915b4d23b740819d2517eec69faee5/00e2af2d9bb645159c1b5fcddd2cb2c6.jpg, createdBy=99845449374, createdName=ms4000000106695679, createdTime=Sun Jul 24 23:31:11 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207893, encodeId=f8fd120e89306, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:癌症<br>经验分享:请问大伙,做癌症和非编码RNA投这个期刊成功率如何,最近投molecular cell悲剧,编辑要转投cell reports,但老板不让,要我再试试NC和NAR。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=科研1995师太, createdTime=Fri Apr 01 17:03:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109930, encodeId=4d9621099301b, content=二区了,还能投吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78855431602, createdName=NJMU-CNS, createdTime=Thu Jan 12 10:08:51 CST 2023, time=2023-01-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=947942, encodeId=08ae94e942eb, content=垃圾杂志,这两年火了非编码RNA否则杂志IF撑不住, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8452423117, createdName=qinss77, createdTime=Sat Mar 13 21:58:24 CST 2021, time=2021-03-13, status=1, ipAttribution=)]
    2022-08-30 ms5000001540302513

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向:微生物检测;感染学;分子诊断
    经验分享:昨天上午刚投稿,目前在in editorial review阶段,这是去年硕士毕业以后在公司发表的第一篇文章,也是在新领域发表的第一篇文章 祝我好运~

    2

    展开2条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=859466, encodeId=c76e859466fb, content=审稿速度:1.0<br>经验分享:nar竟然是二区????????和去年pnas、nature communications“划”到二区一样夸张。好一点的学校都已经有自己的评价体系,而不是跟风中科院分区(中科院分区,中科院很多所自己都不用),情况会逐渐转好。顺便讲个真实的笑话:一个发了一作pnas的朋友去某医学院面试,人事处的老师说,你不就是发了一篇二区文章么! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9195413982, createdName=ms3860263520721591, createdTime=Wed Apr 15 16:58:51 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970593, encodeId=7c849e0593a4, content=in editorial review状态需要多久呢,我的10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52f25512562, createdName=ms2000000504554122, createdTime=Thu Jun 03 15:09:25 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567125, encodeId=644f56e1252d, content=大神,请问需要多久?<span class="quote">tomsyu 2019-01-04 发表::<br>in editorial review这个状态需要多久啊?</span><span class="quote">tomsyu 2019-01-04 00:00:00 发表:<br>in editorial review这个状态需要多久啊?</span>, beContent=tomsyu 2019-01-04 发表:: in editorial review这个状态需要多久啊?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=333, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKt8ibGpwDuX7CGf4Nf1iaeHbqWV9NQUmj1teVPeX2aMx1ic2dghlvnV2TFXibFY7SyCCAl8iaPyicrNOQA/0, createdBy=54821701295, createdName=毛毛们, createdTime=Fri Feb 22 00:00:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242045, encodeId=8b42124204531, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:微生物检测;感染学;分子诊断<br>经验分享:昨天上午刚投稿,目前在in editorial review阶段,这是去年硕士毕业以后在公司发表的第一篇文章,也是在新领域发表的第一篇文章 祝我好运~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=85a68298213, createdName=ms5000001540302513, createdTime=Tue Aug 30 14:05:37 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231564, encodeId=cd051231564fa, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:转录因子<br>经验分享:前面发过一个心得。NAR的意见比较细,reject分两种,一种是完全reject,就算你补充更多的数据也不能再投。第二种reject是可以重投,但是需要大概,文章需要重新写,数据结构需要调整,数据也需要补充。第三种reject是你们说的大修,就是光按照reviewer的要求进行大修即可。是哪一种reject,editor会明确说明。一般来说,第一种的话是觉得你的创新性不够,或者感觉核心数据有严重的问题。我们是第二种。编辑允许重新投。其中一个reviewer的意见有点苛刻。所有的western的图都嫌质量不好,另外就是感觉结论不够generalized,当然还有若干具体的修改或补充实验。其实generalized的问题比较有意思,做心脏的得道的结论非要让在肿瘤上试一下,是不是有点意思。不管怎么样吧,继续努力,希望运气能好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Sat Jul 09 23:52:47 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141273, encodeId=1e3421412e3a5, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:05-Sep-2022 一轮送审<br>27-Sep-2022 大修意见回来<br>27-Feb-2023 二轮送审<br>13-Apr-2023 小修意见回来<br>04-May-2023 三轮送审<br>25-May-2023 三轮意见回来<br>25-May-2023 修改部分书面问题<br>27-May-2023 接收<br><br>总体来说,不太好投,要求比较高,补了很多实验,但大修回去后意见都很positive后,后面二轮三轮就很简单了,关键在于第一轮返修的情况。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b198299181, createdName=ms1000000281250573, createdTime=Wed Jun 07 15:29:37 CST 2023, time=2023-06-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1234512, encodeId=c59e123451205, content=第一轮评审三个审稿人,一个给了reject,一个感觉是major,还有一个minor,然后编辑给了大修<br>二审修回去一个多月了还在in peer-review,比一审还久。。感觉是不是要凉凉了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220202/98915b4d23b740819d2517eec69faee5/00e2af2d9bb645159c1b5fcddd2cb2c6.jpg, createdBy=99845449374, createdName=ms4000000106695679, createdTime=Sun Jul 24 23:31:11 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207893, encodeId=f8fd120e89306, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:癌症<br>经验分享:请问大伙,做癌症和非编码RNA投这个期刊成功率如何,最近投molecular cell悲剧,编辑要转投cell reports,但老板不让,要我再试试NC和NAR。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=科研1995师太, createdTime=Fri Apr 01 17:03:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109930, encodeId=4d9621099301b, content=二区了,还能投吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78855431602, createdName=NJMU-CNS, createdTime=Thu Jan 12 10:08:51 CST 2023, time=2023-01-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=947942, encodeId=08ae94e942eb, content=垃圾杂志,这两年火了非编码RNA否则杂志IF撑不住, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8452423117, createdName=qinss77, createdTime=Sat Mar 13 21:58:24 CST 2021, time=2021-03-13, status=1, ipAttribution=)]
    2022-07-09 franky45

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向:转录因子
    经验分享:前面发过一个心得。NAR的意见比较细,reject分两种,一种是完全reject,就算你补充更多的数据也不能再投。第二种reject是可以重投,但是需要大概,文章需要重新写,数据结构需要调整,数据也需要补充。第三种reject是你们说的大修,就是光按照reviewer的要求进行大修即可。是哪一种reject,editor会明确说明。一般来说,第一种的话是觉得你的创新性不够,或者感觉核心数据有严重的问题。我们是第二种。编辑允许重新投。其中一个reviewer的意见有点苛刻。所有的western的图都嫌质量不好,另外就是感觉结论不够generalized,当然还有若干具体的修改或补充实验。其实generalized的问题比较有意思,做心脏的得道的结论非要让在肿瘤上试一下,是不是有点意思。不管怎么样吧,继续努力,希望运气能好。

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=859466, encodeId=c76e859466fb, content=审稿速度:1.0<br>经验分享:nar竟然是二区????????和去年pnas、nature communications“划”到二区一样夸张。好一点的学校都已经有自己的评价体系,而不是跟风中科院分区(中科院分区,中科院很多所自己都不用),情况会逐渐转好。顺便讲个真实的笑话:一个发了一作pnas的朋友去某医学院面试,人事处的老师说,你不就是发了一篇二区文章么! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9195413982, createdName=ms3860263520721591, createdTime=Wed Apr 15 16:58:51 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970593, encodeId=7c849e0593a4, content=in editorial review状态需要多久呢,我的10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52f25512562, createdName=ms2000000504554122, createdTime=Thu Jun 03 15:09:25 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567125, encodeId=644f56e1252d, content=大神,请问需要多久?<span class="quote">tomsyu 2019-01-04 发表::<br>in editorial review这个状态需要多久啊?</span><span class="quote">tomsyu 2019-01-04 00:00:00 发表:<br>in editorial review这个状态需要多久啊?</span>, beContent=tomsyu 2019-01-04 发表:: in editorial review这个状态需要多久啊?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=333, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKt8ibGpwDuX7CGf4Nf1iaeHbqWV9NQUmj1teVPeX2aMx1ic2dghlvnV2TFXibFY7SyCCAl8iaPyicrNOQA/0, createdBy=54821701295, createdName=毛毛们, createdTime=Fri Feb 22 00:00:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242045, encodeId=8b42124204531, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:微生物检测;感染学;分子诊断<br>经验分享:昨天上午刚投稿,目前在in editorial review阶段,这是去年硕士毕业以后在公司发表的第一篇文章,也是在新领域发表的第一篇文章 祝我好运~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=85a68298213, createdName=ms5000001540302513, createdTime=Tue Aug 30 14:05:37 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231564, encodeId=cd051231564fa, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:转录因子<br>经验分享:前面发过一个心得。NAR的意见比较细,reject分两种,一种是完全reject,就算你补充更多的数据也不能再投。第二种reject是可以重投,但是需要大概,文章需要重新写,数据结构需要调整,数据也需要补充。第三种reject是你们说的大修,就是光按照reviewer的要求进行大修即可。是哪一种reject,editor会明确说明。一般来说,第一种的话是觉得你的创新性不够,或者感觉核心数据有严重的问题。我们是第二种。编辑允许重新投。其中一个reviewer的意见有点苛刻。所有的western的图都嫌质量不好,另外就是感觉结论不够generalized,当然还有若干具体的修改或补充实验。其实generalized的问题比较有意思,做心脏的得道的结论非要让在肿瘤上试一下,是不是有点意思。不管怎么样吧,继续努力,希望运气能好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Sat Jul 09 23:52:47 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141273, encodeId=1e3421412e3a5, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:05-Sep-2022 一轮送审<br>27-Sep-2022 大修意见回来<br>27-Feb-2023 二轮送审<br>13-Apr-2023 小修意见回来<br>04-May-2023 三轮送审<br>25-May-2023 三轮意见回来<br>25-May-2023 修改部分书面问题<br>27-May-2023 接收<br><br>总体来说,不太好投,要求比较高,补了很多实验,但大修回去后意见都很positive后,后面二轮三轮就很简单了,关键在于第一轮返修的情况。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b198299181, createdName=ms1000000281250573, createdTime=Wed Jun 07 15:29:37 CST 2023, time=2023-06-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1234512, encodeId=c59e123451205, content=第一轮评审三个审稿人,一个给了reject,一个感觉是major,还有一个minor,然后编辑给了大修<br>二审修回去一个多月了还在in peer-review,比一审还久。。感觉是不是要凉凉了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220202/98915b4d23b740819d2517eec69faee5/00e2af2d9bb645159c1b5fcddd2cb2c6.jpg, createdBy=99845449374, createdName=ms4000000106695679, createdTime=Sun Jul 24 23:31:11 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207893, encodeId=f8fd120e89306, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:癌症<br>经验分享:请问大伙,做癌症和非编码RNA投这个期刊成功率如何,最近投molecular cell悲剧,编辑要转投cell reports,但老板不让,要我再试试NC和NAR。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=科研1995师太, createdTime=Fri Apr 01 17:03:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109930, encodeId=4d9621099301b, content=二区了,还能投吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78855431602, createdName=NJMU-CNS, createdTime=Thu Jan 12 10:08:51 CST 2023, time=2023-01-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=947942, encodeId=08ae94e942eb, content=垃圾杂志,这两年火了非编码RNA否则杂志IF撑不住, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8452423117, createdName=qinss77, createdTime=Sat Mar 13 21:58:24 CST 2021, time=2021-03-13, status=1, ipAttribution=)]
    2023-06-07 ms1000000281250573 来自广东省

    审稿速度:2.0 | 投稿命中率:25.0
    经验分享:05-Sep-2022 一轮送审
    27-Sep-2022 大修意见回来
    27-Feb-2023 二轮送审
    13-Apr-2023 小修意见回来
    04-May-2023 三轮送审
    25-May-2023 三轮意见回来
    25-May-2023 修改部分书面问题
    27-May-2023 接收

    总体来说,不太好投,要求比较高,补了很多实验,但大修回去后意见都很positive后,后面二轮三轮就很简单了,关键在于第一轮返修的情况。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=859466, encodeId=c76e859466fb, content=审稿速度:1.0<br>经验分享:nar竟然是二区????????和去年pnas、nature communications“划”到二区一样夸张。好一点的学校都已经有自己的评价体系,而不是跟风中科院分区(中科院分区,中科院很多所自己都不用),情况会逐渐转好。顺便讲个真实的笑话:一个发了一作pnas的朋友去某医学院面试,人事处的老师说,你不就是发了一篇二区文章么! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9195413982, createdName=ms3860263520721591, createdTime=Wed Apr 15 16:58:51 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970593, encodeId=7c849e0593a4, content=in editorial review状态需要多久呢,我的10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52f25512562, createdName=ms2000000504554122, createdTime=Thu Jun 03 15:09:25 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567125, encodeId=644f56e1252d, content=大神,请问需要多久?<span class="quote">tomsyu 2019-01-04 发表::<br>in editorial review这个状态需要多久啊?</span><span class="quote">tomsyu 2019-01-04 00:00:00 发表:<br>in editorial review这个状态需要多久啊?</span>, beContent=tomsyu 2019-01-04 发表:: in editorial review这个状态需要多久啊?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=333, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKt8ibGpwDuX7CGf4Nf1iaeHbqWV9NQUmj1teVPeX2aMx1ic2dghlvnV2TFXibFY7SyCCAl8iaPyicrNOQA/0, createdBy=54821701295, createdName=毛毛们, createdTime=Fri Feb 22 00:00:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242045, encodeId=8b42124204531, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:微生物检测;感染学;分子诊断<br>经验分享:昨天上午刚投稿,目前在in editorial review阶段,这是去年硕士毕业以后在公司发表的第一篇文章,也是在新领域发表的第一篇文章 祝我好运~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=85a68298213, createdName=ms5000001540302513, createdTime=Tue Aug 30 14:05:37 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231564, encodeId=cd051231564fa, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:转录因子<br>经验分享:前面发过一个心得。NAR的意见比较细,reject分两种,一种是完全reject,就算你补充更多的数据也不能再投。第二种reject是可以重投,但是需要大概,文章需要重新写,数据结构需要调整,数据也需要补充。第三种reject是你们说的大修,就是光按照reviewer的要求进行大修即可。是哪一种reject,editor会明确说明。一般来说,第一种的话是觉得你的创新性不够,或者感觉核心数据有严重的问题。我们是第二种。编辑允许重新投。其中一个reviewer的意见有点苛刻。所有的western的图都嫌质量不好,另外就是感觉结论不够generalized,当然还有若干具体的修改或补充实验。其实generalized的问题比较有意思,做心脏的得道的结论非要让在肿瘤上试一下,是不是有点意思。不管怎么样吧,继续努力,希望运气能好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Sat Jul 09 23:52:47 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141273, encodeId=1e3421412e3a5, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:05-Sep-2022 一轮送审<br>27-Sep-2022 大修意见回来<br>27-Feb-2023 二轮送审<br>13-Apr-2023 小修意见回来<br>04-May-2023 三轮送审<br>25-May-2023 三轮意见回来<br>25-May-2023 修改部分书面问题<br>27-May-2023 接收<br><br>总体来说,不太好投,要求比较高,补了很多实验,但大修回去后意见都很positive后,后面二轮三轮就很简单了,关键在于第一轮返修的情况。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b198299181, createdName=ms1000000281250573, createdTime=Wed Jun 07 15:29:37 CST 2023, time=2023-06-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1234512, encodeId=c59e123451205, content=第一轮评审三个审稿人,一个给了reject,一个感觉是major,还有一个minor,然后编辑给了大修<br>二审修回去一个多月了还在in peer-review,比一审还久。。感觉是不是要凉凉了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220202/98915b4d23b740819d2517eec69faee5/00e2af2d9bb645159c1b5fcddd2cb2c6.jpg, createdBy=99845449374, createdName=ms4000000106695679, createdTime=Sun Jul 24 23:31:11 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207893, encodeId=f8fd120e89306, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:癌症<br>经验分享:请问大伙,做癌症和非编码RNA投这个期刊成功率如何,最近投molecular cell悲剧,编辑要转投cell reports,但老板不让,要我再试试NC和NAR。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=科研1995师太, createdTime=Fri Apr 01 17:03:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109930, encodeId=4d9621099301b, content=二区了,还能投吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78855431602, createdName=NJMU-CNS, createdTime=Thu Jan 12 10:08:51 CST 2023, time=2023-01-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=947942, encodeId=08ae94e942eb, content=垃圾杂志,这两年火了非编码RNA否则杂志IF撑不住, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8452423117, createdName=qinss77, createdTime=Sat Mar 13 21:58:24 CST 2021, time=2021-03-13, status=1, ipAttribution=)]
    2022-07-24 ms4000000106695679

    第一轮评审三个审稿人,一个给了reject,一个感觉是major,还有一个minor,然后编辑给了大修
    二审修回去一个多月了还在in peer-review,比一审还久。。感觉是不是要凉凉了。。。

    9

    展开9条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=859466, encodeId=c76e859466fb, content=审稿速度:1.0<br>经验分享:nar竟然是二区????????和去年pnas、nature communications“划”到二区一样夸张。好一点的学校都已经有自己的评价体系,而不是跟风中科院分区(中科院分区,中科院很多所自己都不用),情况会逐渐转好。顺便讲个真实的笑话:一个发了一作pnas的朋友去某医学院面试,人事处的老师说,你不就是发了一篇二区文章么! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9195413982, createdName=ms3860263520721591, createdTime=Wed Apr 15 16:58:51 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970593, encodeId=7c849e0593a4, content=in editorial review状态需要多久呢,我的10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52f25512562, createdName=ms2000000504554122, createdTime=Thu Jun 03 15:09:25 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567125, encodeId=644f56e1252d, content=大神,请问需要多久?<span class="quote">tomsyu 2019-01-04 发表::<br>in editorial review这个状态需要多久啊?</span><span class="quote">tomsyu 2019-01-04 00:00:00 发表:<br>in editorial review这个状态需要多久啊?</span>, beContent=tomsyu 2019-01-04 发表:: in editorial review这个状态需要多久啊?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=333, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKt8ibGpwDuX7CGf4Nf1iaeHbqWV9NQUmj1teVPeX2aMx1ic2dghlvnV2TFXibFY7SyCCAl8iaPyicrNOQA/0, createdBy=54821701295, createdName=毛毛们, createdTime=Fri Feb 22 00:00:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242045, encodeId=8b42124204531, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:微生物检测;感染学;分子诊断<br>经验分享:昨天上午刚投稿,目前在in editorial review阶段,这是去年硕士毕业以后在公司发表的第一篇文章,也是在新领域发表的第一篇文章 祝我好运~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=85a68298213, createdName=ms5000001540302513, createdTime=Tue Aug 30 14:05:37 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231564, encodeId=cd051231564fa, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:转录因子<br>经验分享:前面发过一个心得。NAR的意见比较细,reject分两种,一种是完全reject,就算你补充更多的数据也不能再投。第二种reject是可以重投,但是需要大概,文章需要重新写,数据结构需要调整,数据也需要补充。第三种reject是你们说的大修,就是光按照reviewer的要求进行大修即可。是哪一种reject,editor会明确说明。一般来说,第一种的话是觉得你的创新性不够,或者感觉核心数据有严重的问题。我们是第二种。编辑允许重新投。其中一个reviewer的意见有点苛刻。所有的western的图都嫌质量不好,另外就是感觉结论不够generalized,当然还有若干具体的修改或补充实验。其实generalized的问题比较有意思,做心脏的得道的结论非要让在肿瘤上试一下,是不是有点意思。不管怎么样吧,继续努力,希望运气能好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Sat Jul 09 23:52:47 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141273, encodeId=1e3421412e3a5, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:05-Sep-2022 一轮送审<br>27-Sep-2022 大修意见回来<br>27-Feb-2023 二轮送审<br>13-Apr-2023 小修意见回来<br>04-May-2023 三轮送审<br>25-May-2023 三轮意见回来<br>25-May-2023 修改部分书面问题<br>27-May-2023 接收<br><br>总体来说,不太好投,要求比较高,补了很多实验,但大修回去后意见都很positive后,后面二轮三轮就很简单了,关键在于第一轮返修的情况。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b198299181, createdName=ms1000000281250573, createdTime=Wed Jun 07 15:29:37 CST 2023, time=2023-06-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1234512, encodeId=c59e123451205, content=第一轮评审三个审稿人,一个给了reject,一个感觉是major,还有一个minor,然后编辑给了大修<br>二审修回去一个多月了还在in peer-review,比一审还久。。感觉是不是要凉凉了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220202/98915b4d23b740819d2517eec69faee5/00e2af2d9bb645159c1b5fcddd2cb2c6.jpg, createdBy=99845449374, createdName=ms4000000106695679, createdTime=Sun Jul 24 23:31:11 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207893, encodeId=f8fd120e89306, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:癌症<br>经验分享:请问大伙,做癌症和非编码RNA投这个期刊成功率如何,最近投molecular cell悲剧,编辑要转投cell reports,但老板不让,要我再试试NC和NAR。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=科研1995师太, createdTime=Fri Apr 01 17:03:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109930, encodeId=4d9621099301b, content=二区了,还能投吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78855431602, createdName=NJMU-CNS, createdTime=Thu Jan 12 10:08:51 CST 2023, time=2023-01-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=947942, encodeId=08ae94e942eb, content=垃圾杂志,这两年火了非编码RNA否则杂志IF撑不住, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8452423117, createdName=qinss77, createdTime=Sat Mar 13 21:58:24 CST 2021, time=2021-03-13, status=1, ipAttribution=)]
    2022-04-01 科研1995师太

    审稿速度:1.0 | 投稿命中率:5.0
    偏重的研究方向:癌症
    经验分享:请问大伙,做癌症和非编码RNA投这个期刊成功率如何,最近投molecular cell悲剧,编辑要转投cell reports,但老板不让,要我再试试NC和NAR。

    4

    展开4条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=859466, encodeId=c76e859466fb, content=审稿速度:1.0<br>经验分享:nar竟然是二区????????和去年pnas、nature communications“划”到二区一样夸张。好一点的学校都已经有自己的评价体系,而不是跟风中科院分区(中科院分区,中科院很多所自己都不用),情况会逐渐转好。顺便讲个真实的笑话:一个发了一作pnas的朋友去某医学院面试,人事处的老师说,你不就是发了一篇二区文章么! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9195413982, createdName=ms3860263520721591, createdTime=Wed Apr 15 16:58:51 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970593, encodeId=7c849e0593a4, content=in editorial review状态需要多久呢,我的10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52f25512562, createdName=ms2000000504554122, createdTime=Thu Jun 03 15:09:25 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567125, encodeId=644f56e1252d, content=大神,请问需要多久?<span class="quote">tomsyu 2019-01-04 发表::<br>in editorial review这个状态需要多久啊?</span><span class="quote">tomsyu 2019-01-04 00:00:00 发表:<br>in editorial review这个状态需要多久啊?</span>, beContent=tomsyu 2019-01-04 发表:: in editorial review这个状态需要多久啊?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=333, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKt8ibGpwDuX7CGf4Nf1iaeHbqWV9NQUmj1teVPeX2aMx1ic2dghlvnV2TFXibFY7SyCCAl8iaPyicrNOQA/0, createdBy=54821701295, createdName=毛毛们, createdTime=Fri Feb 22 00:00:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242045, encodeId=8b42124204531, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:微生物检测;感染学;分子诊断<br>经验分享:昨天上午刚投稿,目前在in editorial review阶段,这是去年硕士毕业以后在公司发表的第一篇文章,也是在新领域发表的第一篇文章 祝我好运~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=85a68298213, createdName=ms5000001540302513, createdTime=Tue Aug 30 14:05:37 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231564, encodeId=cd051231564fa, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:转录因子<br>经验分享:前面发过一个心得。NAR的意见比较细,reject分两种,一种是完全reject,就算你补充更多的数据也不能再投。第二种reject是可以重投,但是需要大概,文章需要重新写,数据结构需要调整,数据也需要补充。第三种reject是你们说的大修,就是光按照reviewer的要求进行大修即可。是哪一种reject,editor会明确说明。一般来说,第一种的话是觉得你的创新性不够,或者感觉核心数据有严重的问题。我们是第二种。编辑允许重新投。其中一个reviewer的意见有点苛刻。所有的western的图都嫌质量不好,另外就是感觉结论不够generalized,当然还有若干具体的修改或补充实验。其实generalized的问题比较有意思,做心脏的得道的结论非要让在肿瘤上试一下,是不是有点意思。不管怎么样吧,继续努力,希望运气能好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Sat Jul 09 23:52:47 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141273, encodeId=1e3421412e3a5, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:05-Sep-2022 一轮送审<br>27-Sep-2022 大修意见回来<br>27-Feb-2023 二轮送审<br>13-Apr-2023 小修意见回来<br>04-May-2023 三轮送审<br>25-May-2023 三轮意见回来<br>25-May-2023 修改部分书面问题<br>27-May-2023 接收<br><br>总体来说,不太好投,要求比较高,补了很多实验,但大修回去后意见都很positive后,后面二轮三轮就很简单了,关键在于第一轮返修的情况。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b198299181, createdName=ms1000000281250573, createdTime=Wed Jun 07 15:29:37 CST 2023, time=2023-06-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1234512, encodeId=c59e123451205, content=第一轮评审三个审稿人,一个给了reject,一个感觉是major,还有一个minor,然后编辑给了大修<br>二审修回去一个多月了还在in peer-review,比一审还久。。感觉是不是要凉凉了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220202/98915b4d23b740819d2517eec69faee5/00e2af2d9bb645159c1b5fcddd2cb2c6.jpg, createdBy=99845449374, createdName=ms4000000106695679, createdTime=Sun Jul 24 23:31:11 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207893, encodeId=f8fd120e89306, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:癌症<br>经验分享:请问大伙,做癌症和非编码RNA投这个期刊成功率如何,最近投molecular cell悲剧,编辑要转投cell reports,但老板不让,要我再试试NC和NAR。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=科研1995师太, createdTime=Fri Apr 01 17:03:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109930, encodeId=4d9621099301b, content=二区了,还能投吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78855431602, createdName=NJMU-CNS, createdTime=Thu Jan 12 10:08:51 CST 2023, time=2023-01-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=947942, encodeId=08ae94e942eb, content=垃圾杂志,这两年火了非编码RNA否则杂志IF撑不住, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8452423117, createdName=qinss77, createdTime=Sat Mar 13 21:58:24 CST 2021, time=2021-03-13, status=1, ipAttribution=)]
    2023-01-12 NJMU-CNS 来自江苏省

    二区了,还能投吗?

    1

    展开1条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=859466, encodeId=c76e859466fb, content=审稿速度:1.0<br>经验分享:nar竟然是二区????????和去年pnas、nature communications“划”到二区一样夸张。好一点的学校都已经有自己的评价体系,而不是跟风中科院分区(中科院分区,中科院很多所自己都不用),情况会逐渐转好。顺便讲个真实的笑话:一个发了一作pnas的朋友去某医学院面试,人事处的老师说,你不就是发了一篇二区文章么! , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=223, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9195413982, createdName=ms3860263520721591, createdTime=Wed Apr 15 16:58:51 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970593, encodeId=7c849e0593a4, content=in editorial review状态需要多久呢,我的10天了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=203, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=52f25512562, createdName=ms2000000504554122, createdTime=Thu Jun 03 15:09:25 CST 2021, time=2021-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567125, encodeId=644f56e1252d, content=大神,请问需要多久?<span class="quote">tomsyu 2019-01-04 发表::<br>in editorial review这个状态需要多久啊?</span><span class="quote">tomsyu 2019-01-04 00:00:00 发表:<br>in editorial review这个状态需要多久啊?</span>, beContent=tomsyu 2019-01-04 发表:: in editorial review这个状态需要多久啊?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=333, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKt8ibGpwDuX7CGf4Nf1iaeHbqWV9NQUmj1teVPeX2aMx1ic2dghlvnV2TFXibFY7SyCCAl8iaPyicrNOQA/0, createdBy=54821701295, createdName=毛毛们, createdTime=Fri Feb 22 00:00:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1242045, encodeId=8b42124204531, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:微生物检测;感染学;分子诊断<br>经验分享:昨天上午刚投稿,目前在in editorial review阶段,这是去年硕士毕业以后在公司发表的第一篇文章,也是在新领域发表的第一篇文章 祝我好运~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=107, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=85a68298213, createdName=ms5000001540302513, createdTime=Tue Aug 30 14:05:37 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231564, encodeId=cd051231564fa, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:转录因子<br>经验分享:前面发过一个心得。NAR的意见比较细,reject分两种,一种是完全reject,就算你补充更多的数据也不能再投。第二种reject是可以重投,但是需要大概,文章需要重新写,数据结构需要调整,数据也需要补充。第三种reject是你们说的大修,就是光按照reviewer的要求进行大修即可。是哪一种reject,editor会明确说明。一般来说,第一种的话是觉得你的创新性不够,或者感觉核心数据有严重的问题。我们是第二种。编辑允许重新投。其中一个reviewer的意见有点苛刻。所有的western的图都嫌质量不好,另外就是感觉结论不够generalized,当然还有若干具体的修改或补充实验。其实generalized的问题比较有意思,做心脏的得道的结论非要让在肿瘤上试一下,是不是有点意思。不管怎么样吧,继续努力,希望运气能好。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5a161653750, createdName=franky45, createdTime=Sat Jul 09 23:52:47 CST 2022, time=2022-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141273, encodeId=1e3421412e3a5, content=审稿速度:2.0 | 投稿命中率:25.0<br>经验分享:05-Sep-2022 一轮送审<br>27-Sep-2022 大修意见回来<br>27-Feb-2023 二轮送审<br>13-Apr-2023 小修意见回来<br>04-May-2023 三轮送审<br>25-May-2023 三轮意见回来<br>25-May-2023 修改部分书面问题<br>27-May-2023 接收<br><br>总体来说,不太好投,要求比较高,补了很多实验,但大修回去后意见都很positive后,后面二轮三轮就很简单了,关键在于第一轮返修的情况。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7b198299181, createdName=ms1000000281250573, createdTime=Wed Jun 07 15:29:37 CST 2023, time=2023-06-07, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1234512, encodeId=c59e123451205, content=第一轮评审三个审稿人,一个给了reject,一个感觉是major,还有一个minor,然后编辑给了大修<br>二审修回去一个多月了还在in peer-review,比一审还久。。感觉是不是要凉凉了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=112, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220202/98915b4d23b740819d2517eec69faee5/00e2af2d9bb645159c1b5fcddd2cb2c6.jpg, createdBy=99845449374, createdName=ms4000000106695679, createdTime=Sun Jul 24 23:31:11 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1207893, encodeId=f8fd120e89306, content=审稿速度:1.0 | 投稿命中率:5.0<br>偏重的研究方向:癌症<br>经验分享:请问大伙,做癌症和非编码RNA投这个期刊成功率如何,最近投molecular cell悲剧,编辑要转投cell reports,但老板不让,要我再试试NC和NAR。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=132, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=90b25397444, createdName=科研1995师太, createdTime=Fri Apr 01 17:03:49 CST 2022, time=2022-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2109930, encodeId=4d9621099301b, content=二区了,还能投吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=87, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78855431602, createdName=NJMU-CNS, createdTime=Thu Jan 12 10:08:51 CST 2023, time=2023-01-12, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=947942, encodeId=08ae94e942eb, content=垃圾杂志,这两年火了非编码RNA否则杂志IF撑不住, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=176, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e8452423117, createdName=qinss77, createdTime=Sat Mar 13 21:58:24 CST 2021, time=2021-03-13, status=1, ipAttribution=)]
    2021-03-13 qinss77

    垃圾杂志,这两年火了非编码RNA否则杂志IF撑不住

    1

    展开1条回复
共109条页码: 1/11页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分